← Back to Search

Serotonin Inverse Agonist/Antagonist

Pimavanserin for Neuropsychiatric Symptoms

Phase 3
Waitlist Available
Research Sponsored by ACADIA Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up treatment period and follow-up period: 56 weeks
Awards & highlights

Study Summary

This trial will study the safety and tolerability of the drug pimavanserin when taken by adults and elderly patients with neuropsychiatric symptoms related to neurodegenerative diseases, over the course of 52 weeks.

Eligible Conditions
  • Neuropsychiatric Symptoms of Neurodegenerative Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~treatment period and follow-up period: 56 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and treatment period and follow-up period: 56 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
• Treatment-emergent adverse events (TEAEs)

Side effects data

From 2021 Phase 4 trial • 6 Patients • NCT04188392
33%
sleepiness
17%
diarrhea
17%
weight gain
17%
arthralgia
17%
dry mouth
17%
headache
17%
skin irritation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Open-label Treatment

Trial Design

1Treatment groups
Experimental Treatment
Group I: Drug - pimavanserinExperimental Treatment1 Intervention
Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pimavanserin
2018
Completed Phase 4
~3010

Find a Location

Who is running the clinical trial?

ACADIA Pharmaceuticals Inc.Lead Sponsor
46 Previous Clinical Trials
10,345 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA given Pimavanserin their blessing?

"Pimavanserin's safety is well supported by multiple clinical trials and Phase 3 data, so it received a score of 3."

Answered by AI

Are there any other instances of Pimavanserin being studied in a clinical setting?

"At this moment in time, there are 6 ongoing studies involving Pimavanserin. 3 of these live studies are currently in Phase 3 clinical trials. The majority of the research for Pimavanserin takes place in Gdańsk and Arizona; however, 414 different locations around the world are running trials for this treatment."

Answered by AI

Are there any available places for patients in this research project?

"This is an inactive clinical trial, which was originally posted on July 17th, 2018. The last update to the listing was on October 10th, 2022. There are 56 other trials that may be a better match for patients right now."

Answered by AI

Who else is applying?

What state do they live in?
California
What site did they apply to?
ATP Clinical Research, Inc.
Wasatch Clinical Research
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

What questions have other patients asked about this trial?

How long of a program is this? How many visits to the facility will there be?
PatientReceived 1 prior treatment
~89 spots leftby Mar 2025